Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia

Chronic lymphocytic leukemia (CLL) is common in both developed and developing nations where the need for inexpensive and convenient administration of therapy is apparent. Ocaratuzumab is a novel Fc-engineered humanized IgG1 anti-CD20 monoclonal antibody (mAb) designed for effective antibody-dependen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Cheney, Carolyn M, Stephens, Deborah M, Mo, Xiaokui, Rafiq, Sarwish, Butchar, Jonathan, Flynn, Joseph M, Jones, Jeffrey A, Maddocks, Kami, O’Reilly, Adrienne, Ramachandran, Abhijit, Tridandapani, Susheela, Muthusamy, Natarajan, Byrd, John C
Formato: Artigo
Idioma:Inglês
Publicado em: Landes Bioscience 2014
Assuntos:
Report
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4011919/
https://ncbi.nlm.nih.gov/pubmed/24594909
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/mabs.28282
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados